Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by FarmerBetsyon Aug 23, 2023 6:53pm
159 Views
Post# 35602872

RE:RE:RE:RE:RE:RE:RE:RE:RE:And there you have it.

RE:RE:RE:RE:RE:RE:RE:RE:RE:And there you have it. M101, your reading in the wrong place. The more whistleblowers the more traction maybe. No one is accusing of wrong doing but what just happened does not pass the smell test. Participate like others and see what comes out of the SEC, at a minimum files are started. 

Re-Cap Nasdaq
Promis shares out on the market about 8.5 million
July 1 -16 all trading days total up to 65,554 shares traded.
July -17th shares traded 13,926,020 shares traded, Unprecedented in history of the company.
July -17th share high $ 8.95 close at $ 6.19
July -21, TSX trading delisted
July-24 ,  5 trading days later closes at $ 1.75 near an all time cmpy low since 2007
Aug- 21, PIPE announced financing of approx- 20 million at $1.88 per unit plus warrants when market cap of company is 13 million?

Other considerations since new CEO in September appears to be a lack of transparency. Appears to be a lack of public relations, social media all but eliminated, website information outdated and incorrect, commentary, video, corporate presentations in the news all old info. 
Small  group 104 total shareholders as per SEC filings earlier this year.
Heavy presence with Boston investors a couple Mike Gordon of Fenway Sports Group and Jeremy Sclar WS Development Group already own approx- 20% of Promis prior to this financing. 

This does not pass the smell test with Promis Management and the BOD what they just did and it's so blatant. If you investors want to be around a little longer you better get on board and say something or your done. sec.gov/whistleblower

Submit a tip!!










<< Previous
Bullboard Posts
Next >>